Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 Teras, 2016, 2016 US lymphoid malignancy statistics by World Health Organization subtypes, CA Cancer J Clin, 66, 443, 10.3322/caac.21357 Novero, 2014, Ibrutinib for B cell malignancies, Exp Hematol Oncol, 3, 4, 10.1186/2162-3619-3-4 Leong, 2016, The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis, Blood, 128, 138, 10.1182/blood-2016-05-712828 Caron, 2017, Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis, Blood Adv, 1, 772, 10.1182/bloodadvances.2016001883 Varughese, 2018, Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer, Clin Infect Dis, 67, 687, 10.1093/cid/ciy175 Tillman, 2018, Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies, Eur J Haematol, 100, 325, 10.1111/ejh.13020 Rogers, 2018, Ibrutinib and fungus: an invasive concern, Blood, 131, 1882, 10.1182/blood-2018-02-832154 Ravandi, 2006, Immune defects in patients with chronic lymphocytic leukemia, Cancer Immunol Immunother, 55, 197, 10.1007/s00262-005-0015-8 Forconi, 2015, Perturbation of the normal immune system in patients with CLL, Blood, 126, 573, 10.1182/blood-2015-03-567388 Crassini, 2018, Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in chronic lymphocytic leukaemia, Br J Haematol, 181, 97, 10.1111/bjh.15146 Sun, 2015, Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib, Blood, 126, 2213, 10.1182/blood-2015-04-639203 Ball, 2018, Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?, Eur J Haematol, 101, 418, 10.1111/ejh.13098 DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Guevara, 2004, Meta-analytic methods for pooling rates when follow-up duration varies: a case study, BMC Med Res Methodol, 4, 17, 10.1186/1471-2288-4-17 Byrd, 2014, Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia, N Engl J Med, 371, 213, 10.1056/NEJMoa1400376 Burger, 2015, Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia, N Engl J Med, 373, 2425, 10.1056/NEJMoa1509388 Chanan-Khan, 2016, Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study, Lancet Oncol, 17, 200, 10.1016/S1470-2045(15)00465-9 Huang, 2018, Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study, Cancer Med, 7, 1043, 10.1002/cam4.1337 Dimopoulos, 2018, Phase 3 trial of ibrutinib plus rituximab in waldenstrom’s macroglobulinemia, N Engl J Med, 378, 2399, 10.1056/NEJMoa1802917 Rule, 2018, Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study, Leukemia, 32, 1799, 10.1038/s41375-018-0023-2 Woyach, 2018, Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL, N Engl J Med, 379, 2517, 10.1056/NEJMoa1812836 Herrera, 2014, Ibrutinib for the treatment of mantle cell lymphoma, Clin Cancer Res, 20, 5365, 10.1158/1078-0432.CCR-14-0010 Ahn, 2016, Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib, Blood, 128, 1940, 10.1182/blood-2016-06-722991 Swan, 2018, Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature, BMJ Case Rep, 2018 Diamantopoulos, 2017, Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib, Ann Hematol, 96, 1049, 10.1007/s00277-017-2964-3 Chan, 2017, Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia, Ann Hematol, 96, 871, 10.1007/s00277-017-2944-7 Williams, 2018, Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies, Leuk Lymphoma, 59, 625, 10.1080/10428194.2017.1347931 Rogers, 2017, Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center, Blood, 130, 830, 10.1182/blood.V130.Suppl_1.830.830 Ghez, 2018, Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib, Blood, 131, 1955, 10.1182/blood-2017-11-818286 Morrison, 2009, Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis, Clin Lymphoma Myeloma, 9, 365, 10.3816/CLM.2009.n.071 Herbst, 2015, Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus, EMBO Mol Med, 7, 240, 10.15252/emmm.201404556 Colado, 2018, Effect of the BTK inhibitor ibrutinib on macrophage- and gammadelta T cell-mediated response against Mycobacterium tuberculosis, Blood Cancer J, 8, 100, 10.1038/s41408-018-0136-x